Commonwealth Equity Services LLC Sells 557 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Commonwealth Equity Services LLC lowered its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 10,455 shares of the medical instruments supplier’s stock after selling 557 shares during the period. Commonwealth Equity Services LLC’s holdings in LeMaitre Vascular were worth $860,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. YHB Investment Advisors Inc. purchased a new stake in LeMaitre Vascular during the 1st quarter valued at approximately $36,000. GAMMA Investing LLC increased its holdings in LeMaitre Vascular by 57.0% in the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 199 shares during the last quarter. West Oak Capital LLC bought a new stake in LeMaitre Vascular in the 2nd quarter valued at $58,000. SG Americas Securities LLC purchased a new stake in LeMaitre Vascular in the 2nd quarter worth $177,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in shares of LeMaitre Vascular during the 1st quarter valued at about $206,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $88.82 on Wednesday. The firm has a market capitalization of $1.99 billion, a PE ratio of 58.82, a PEG ratio of 2.28 and a beta of 0.88. The stock’s fifty day moving average is $86.55 and its 200 day moving average is $77.67. LeMaitre Vascular, Inc. has a fifty-two week low of $44.27 and a fifty-two week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same quarter in the prior year, the firm posted $0.37 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. Equities analysts forecast that LeMaitre Vascular, Inc. will post 1.85 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.72%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s payout ratio is currently 42.38%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Barrington Research boosted their target price on LeMaitre Vascular from $79.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Roth Mkm reaffirmed a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a report on Friday, May 31st. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. JMP Securities upped their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective for the company. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.40.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares in the company, valued at $168,944,956.56. The disclosure for this sale can be found here. Insiders sold 43,251 shares of company stock worth $3,714,994 over the last 90 days. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.